Lilly Endowment reports 30 Eli Lilly (LLY) stock sales on Form 4
Rhea-AI Filing Summary
Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), reported a series of open-market sales of Eli Lilly common stock on 11/25/2025. The Form 4 lists 30 separate sale transactions, each coded as an "S" for sale, with weighted average prices including $1,073.735 and $1,107.48 per share, and footnotes detailing underlying trade ranges from $1,073.78 to $1,107.95. After completing these reported sales, Lilly Endowment Inc. beneficially owned 92,212,610 shares of Eli Lilly common stock, held directly. This filing is identified as the first of two Forms 4 filed the same day, covering transactions numbered 1 through 30 of 33 total.
Positive
- None.
Negative
- None.
Insights
Large 10% owner executed sizable open‑market sales but retains a very substantial direct stake.
The filing shows **Lilly Endowment Inc.**, a checked **10% owner**, selling multiple blocks of **Common Stock** on
The prices span a tight range from about
The remarks state this is the first of two Forms 4 filed on
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,481 | $1,073.735 | $2.66M |
| Sale | Common Stock | 882 | $1,075.997 | $949K |
| Sale | Common Stock | 800 | $1,077.988 | $862K |
| Sale | Common Stock | 1,260 | $1,079.367 | $1.36M |
| Sale | Common Stock | 651 | $1,080.733 | $704K |
| Sale | Common Stock | 1,606 | $1,081.90 | $1.74M |
| Sale | Common Stock | 160 | $1,082.933 | $173K |
| Sale | Common Stock | 3,069 | $1,084.702 | $3.33M |
| Sale | Common Stock | 5,604 | $1,086.069 | $6.09M |
| Sale | Common Stock | 6,508 | $1,086.941 | $7.07M |
| Sale | Common Stock | 5,589 | $1,087.965 | $6.08M |
| Sale | Common Stock | 5,284 | $1,088.907 | $5.75M |
| Sale | Common Stock | 1,907 | $1,089.854 | $2.08M |
| Sale | Common Stock | 5,927 | $1,091.116 | $6.47M |
| Sale | Common Stock | 18,254 | $1,092.058 | $19.93M |
| Sale | Common Stock | 9,050 | $1,093.164 | $9.89M |
| Sale | Common Stock | 6,246 | $1,094.026 | $6.83M |
| Sale | Common Stock | 2,083 | $1,094.794 | $2.28M |
| Sale | Common Stock | 1,061 | $1,096.329 | $1.16M |
| Sale | Common Stock | 4,198 | $1,097.443 | $4.61M |
| Sale | Common Stock | 4,639 | $1,098.315 | $5.10M |
| Sale | Common Stock | 6,545 | $1,099.485 | $7.20M |
| Sale | Common Stock | 8,527 | $1,100.336 | $9.38M |
| Sale | Common Stock | 11,854 | $1,101.449 | $13.06M |
| Sale | Common Stock | 7,456 | $1,102.346 | $8.22M |
| Sale | Common Stock | 6,274 | $1,103.576 | $6.92M |
| Sale | Common Stock | 5,196 | $1,104.411 | $5.74M |
| Sale | Common Stock | 2,494 | $1,105.32 | $2.76M |
| Sale | Common Stock | 3,662 | $1,106.573 | $4.05M |
| Sale | Common Stock | 7,794 | $1,107.48 | $8.63M |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.78 to $1,074.77, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (27), (28), (29), and (30) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,075.50 to $1,076.47, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,077.64 to $1,078.38, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,078.84 to $1,079.52, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,080.10 to $1,081.00, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,081.36 to $1,082.25, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,082.82 to $1,083.00, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,084.50 to $1,085.45, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.50 to $1,086.45, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.50 to $1,087.49, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.50 to $1,088.48, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.47, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.51 to $1,090.46, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.57 to $1,091.55, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.58 to $1,092.57, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,092.58 to $1,093.57, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.58 to $1,094.53, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.65 to $1,095.32, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.86 to $1,096.70, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.86, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.84, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.85, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.87 to $1,100.83, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.87 to $1,101.86, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.87 to $1,102.86, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.97 to $1,103.96, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.97 to $1,104.96, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.97 to $1,105.96, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.99 to $1,106.98, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.00 to $1,107.95, inclusive.
FAQ
What does Eli Lilly (LLY)âs latest Form 4 report?
The Form 4 reports that Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), executed multiple open-market sales of Eli Lilly common stock on 11/25/2025, recorded as 30 separate sale transactions.
What price range did the Eli Lilly (LLY) insider sales occur at?
The sales are reported using weighted average prices such as $1,073.735 and $1,107.48 per share, with footnotes stating underlying transaction ranges from about $1,073.78 up to $1,107.95 per share.
Does the Form 4 show any derivative securities for Eli Lilly (LLY)?
The filing includes a heading for Table II â Derivative Securities, but in the provided content there are no specific derivative transactions or holdings populated in that table.
Is this the only Form 4 filed by Lilly Endowment Inc. on these Eli Lilly (LLY) trades?
No. The remarks explain that this is the first of two Forms 4 filed by the reporting person on November 26, 2025, covering transactions numbered 1 through 30 of a total of 33 transactions.